US

Dubai launches US$ 136 million venture capital fund designed to finance technology startups

Retrieved on: 
Wednesday, November 8, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231108571658/en/
    Dubai launches US$ 136 million venture capital fund designed to finance technology startups (Photo: AETOSWire)
    Launched in the presence of His Highness Sheikh Ahmed bin Mohammed bin Rashid Al Maktoum, Second Deputy Ruler of Dubai, the fund is designed to finance technology startups and supports the economic objectives outlined in the Dubai Economic Agenda, D33 by promoting SMEs growth in various emerging sectors.
  • The new fund was launched on the sidelines of the Dubai Business Forum, which was organised by Dubai Chambers under the patronage of HH Sheikh Mohammed bin Rashid Al Maktoum.
  • The fund is the first investment programme launched under the name of Oraseya Capital, the venture capital arm of DIEZ specialising in venture investment operations in startups.
  • It will play a pivotal role in supporting startups from the pre-seed stage, and extending all the way to the Series B investment stage.

Pan American Silver Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 7, 2023

Pan American Silver Corp. (NYSE: PAAS) (TSX: PAAS) ("Pan American" or the "Company") reports unaudited results for the quarter ended September 30, 2023 ("Q3 2023").

Key Points: 
  • Pan American Silver Corp. (NYSE: PAAS) (TSX: PAAS) ("Pan American" or the "Company") reports unaudited results for the quarter ended September 30, 2023 ("Q3 2023").
  • Silver production was at the low end and gold production was slightly below management's guidance ranges for Q3 2023.
  • Silver Segment Cash Costs and All-in Sustaining Costs ("AISC") per silver ounce of $13.13 and $18.19, respectively.
  • A cash dividend of $0.10 per common share with respect to Q3 2023 was declared on November 7, 2023, payable on or about December 1, 2023, to holders of record of Pan American’s common shares as of the close of markets on November 20, 2023.

New Study Confirms Power of Real-World Data in Proactive Signal Detection, Improving Patient Safety

Retrieved on: 
Wednesday, November 8, 2023

BOSTON, Nov. 8, 2023 /PRNewswire/ -- ArisGlobal, creator of the LifeSphere® technology platform and a market leader in global patient treatment solutions, has announced striking new study results confirming the power of Proactive Safety Signal Detection in improving patient safety. Specifically, the findings support the technology's ability to distill precise, meaningful drug-event insights directly and efficiently from real-world data, boosting drug safety – while potentially also supporting new indications.

Key Points: 
  • A foundational and comparative study of ArisGlobal's LifeSphere® Proactive Signal Detection technology, drew on 12 years of Individual Case Safety Reports (ICSRs) (over 6 million, from Vigibase) and EMR and claims records (18,000, c/o Patient Lives).
  • She commented: "Our innovative and proven Proactive Signal Detection technology will revolutionize Pharmacovigilance (PV) with a direct impact on patient safety, as well as a drug's addressable market.
  • "But now smart analytics, applied to robust real-world data, makes comprehensive, proactive signal detection a reliable reality.
  • ArisGlobal's CEO, Mike Gordon, commented, "Proactive signal detection that leverages real-world data will transform patient safety, while overcoming many of the frustrations experienced by drug companies, regulators and clinicians around post-market drug monitoring."

New Study Confirms Power of Real-World Data in Proactive Signal Detection, Improving Patient Safety

Retrieved on: 
Wednesday, November 8, 2023

BOSTON, Nov. 8, 2023 /PRNewswire/ -- ArisGlobal, creator of the LifeSphere® technology platform and a market leader in global patient treatment solutions, has announced striking new study results confirming the power of Proactive Safety Signal Detection in improving patient safety. Specifically, the findings support the technology's ability to distill precise, meaningful drug-event insights directly and efficiently from real-world data, boosting drug safety – while potentially also supporting new indications.

Key Points: 
  • A foundational and comparative study of ArisGlobal's LifeSphere® Proactive Signal Detection technology, drew on 12 years of Individual Case Safety Reports (ICSRs) (over 6 million, from Vigibase) and EMR and claims records (18,000, c/o Patient Lives).
  • She commented: "Our innovative and proven Proactive Signal Detection technology will revolutionize Pharmacovigilance (PV) with a direct impact on patient safety, as well as a drug's addressable market.
  • "But now smart analytics, applied to robust real-world data, makes comprehensive, proactive signal detection a reliable reality.
  • ArisGlobal's CEO, Mike Gordon, commented, "Proactive signal detection that leverages real-world data will transform patient safety, while overcoming many of the frustrations experienced by drug companies, regulators and clinicians around post-market drug monitoring."

Global 3D Printing in Education Market Surges to $305.2 Billion in 2022, Poised for Impressive 10.90% CAGR Growth by 2028

Retrieved on: 
Tuesday, November 7, 2023

The global 3D printing in education market is witnessing significant growth, with the market size reaching US$ 305.2 billion in 2022.

Key Points: 
  • The global 3D printing in education market is witnessing significant growth, with the market size reaching US$ 305.2 billion in 2022.
  • Industry analysts project robust expansion in the coming years, with the market expected to reach US$ 563.04 billion by 2028, reflecting an impressive Compound Annual Growth Rate (CAGR) of 10.90% during the period from 2023 to 2028.
  • 3D printing in education involves the integration of 3D printers and related technologies to enhance teaching and learning experiences in educational settings.
  • Advancements in 3D printing technology and the emphasis on STEAM education further contribute to its growth.

Enhanced Efficiency and Transparency: E-Invoicing Market Analysis, Segmentation, and Growth Projections 2023-2028

Retrieved on: 
Tuesday, November 7, 2023

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- The "E-Invoicing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 7, 2023 /PRNewswire/ -- The "E-Invoicing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global e-invoicing market is experiencing substantial growth, with the market size reaching US$ 11.2 billion in 2022.
  • E-invoicing offers several advantages, such as enhanced invoice accuracy, improved data quality, reduced payment delays, faster invoice processing, and increased transparency.
  • The report provides a comprehensive analysis of the global e-invoicing market, including forecasts at the global, regional, and country levels from 2023 to 2028.

Global Source-to-Pay Outsourcing Market Hits $27.59 Billion in 2022, Set for Impressive 12.57% CAGR Growth by 2028

Retrieved on: 
Tuesday, November 7, 2023

The global source-to-pay outsourcing market is experiencing remarkable growth, with the market size reaching US$ 27.59 billion in 2022.

Key Points: 
  • The global source-to-pay outsourcing market is experiencing remarkable growth, with the market size reaching US$ 27.59 billion in 2022.
  • Forecasts indicate robust expansion in the coming years, with the market expected to reach US$ 55.8 billion by 2028, reflecting a compelling Compound Annual Growth Rate (CAGR) of 12.57% during the period from 2023 to 2028.
  • Source-to-pay (S2P) outsourcing is a financial arrangement where companies delegate their purchasing and procurement tasks to a third-party service provider.
  • The market is flourishing due to the growth of public and private organizations and their increasing adoption of S2P outsourcing.

Pacific Green Enters Into Transaction to Sell Its 249MW / 373.5MWh Sheaf Energy Park Battery Development for an Enterprise Value of £210 Million (US$258 Million)

Retrieved on: 
Tuesday, November 7, 2023

Dover, DE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacific Green Technologies, Inc. ("Pacific Green", OTCQB: PGTK) announces that it has entered into a transaction to sell 100% of the shares in Pacific Green Battery Energy Parks 2 Limited (“PGBEP2”) to Sosteneo Fund 1 HoldCo S.à.r.l.

Key Points: 
  • Dover, DE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacific Green Technologies, Inc. ("Pacific Green", OTCQB: PGTK) announces that it has entered into a transaction to sell 100% of the shares in Pacific Green Battery Energy Parks 2 Limited (“PGBEP2”) to Sosteneo Fund 1 HoldCo S.à.r.l.
  • (“Sosteneo HoldCo”) for £210 million (US$258 million) (the “Transaction”).
  • PGBEP2 is the holding company for 100% subsidiary, Sheaf Energy Limited, Pacific Green’s 249 MW / 373.5 MWh battery energy storage system in Kent, England (“Sheaf Energy Park”), which will begin commercial operations in July 2025.
  • Under the terms of the Transaction, Pacific Green and Sosteneo have granted each other respective options to buy or sell the shares in PGBEP2.

Stella-Jones Announces Third Quarter Results

Retrieved on: 
Tuesday, November 7, 2023

Sales in the third quarter of 2023 increased by 13% to $949 million, compared to sales of $842 million last year.

Key Points: 
  • Sales in the third quarter of 2023 increased by 13% to $949 million, compared to sales of $842 million last year.
  • The increase was driven by higher pricing as sales volumes remained relatively unchanged when compared to the same quarter last year but were higher versus the prior quarter.
  • In the third quarter of 2023, production volumes continued to increase, benefiting from additional capacity stemming from capital projects.
  • The decrease in sales compared to the third quarter last year was largely attributable to less lumber trading activity.

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Retrieved on: 
Tuesday, November 7, 2023

It was discovered by Dr. Stephen Neidle’s team at the University College London and exclusively licensed by Qualigen in January 2021.

Key Points: 
  • It was discovered by Dr. Stephen Neidle’s team at the University College London and exclusively licensed by Qualigen in January 2021.
  • Qualigen received Orphan Drug Designation for the intended treatment of pancreatic cancer in January and clearance from the US FDA to initiate a Phase 1 clinical trial in July of this year.
  • Qualigen anticipates providing an update on safety and preliminary efficacy of the Phase 1a study in the first half of 2024.
  • For more information on QN-302 or the Phase 1a clinical trial, please visit our QN-302 clinical trial website on ClinicalTrials.gov.